Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis
Nature Medicine · 2025-03 · 31 (3) · 988-995
DOI: 10.1038/s41591-024-03480-y ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nature Medicine, online erschienen am 27.01.2025. Verfasst von Ali Aminian und 16 weiteren Autor:innen. Beteiligte Einrichtung: Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Fatty Liver, Obesity, Liver. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
No therapy has been shown to reduce the risk of major adverse liver outcomes (MALO) in patients with cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). The Surgical Procedures Eliminate Compensated Cirrhosis In Advancing Long-term (SPECCIAL) observational study compared the effects of metabolic surgery and nonsurgical treatment in patients with obesity and compensated histologically proven MASH-related cirrhosis. Using a doubly robust estimation methodology to balance key baseline characteristics between groups, the time-to-incident MALO was compared between 62 patients (68% female) who underwent metabolic surgery and 106 nonsurgical controls (71% female), with a mean follow-up of 10.0 ± 4.5 years. The 15 year cumulative incidence of MALO was 20.9% (95% confidence interval (CI), 2.5-35.9%) in the surgical group compared with 46.4% (95% CI, 25.6-61.3%) in the nonsurgical group, with an adjusted hazard ratio of 0.28 (95% CI, 0.12-0.64), P = 0.003. The 15 year cumulative incidence of decompensated cirrhosis was 15.6% (95% CI, 0-31.3%) in the surgical group compared with 30.7% (95% CI, 12.9-44.8%) in the nonsurgical group, with an adjusted hazard ratio of 0.20 (95% CI, 0.06-0.68), P = 0.01. Among patients with compensated MASH-related cirrhosis and obesity, metabolic surgery, compared with nonsurgical management, was associated with a significantly lower risk of incident MALO. In the absence of approved medical therapies for compensated MASH-related cirrhosis, metabolic surgery may represent a safe and effective therapeutic option to influence the trajectory of cirrhosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, Cleveland, OH, USA.
- Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
- Department of Pathology, Cleveland Clinic, Cleveland, OH, USA.
- MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, San Diego, CA, USA.
- Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, VCU School of Medicine, Richmond, VA, USA.
- Fatty Liver Program, Arizona Liver Health, Chandler, AZ, USA.
Zitieren
APA
Aminian, A., Aljabri, A., Wang, S., Bena, J., Allende, D. S., Rosen, H., Arnold, E., Wilson, R., Milinovich, A., Loomba, R., Sanyal, A. J., Alkhouri, N., Wakim-Fleming, J., Laique, S. N., Dasarathy, S., McCullough, A. J., & Nissen, S. E. (2025). Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis. Nature Medicine, 31(3), 988-995. https://doi.org/10.1038/s41591-024-03480-y
Vancouver
Aminian A, Aljabri A, Wang S, Bena J, Allende DS, Rosen H, et al. Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis. Nature Medicine. 2025;31(3):988-995. doi:10.1038/s41591-024-03480-y
BibTeX
@article{Aminian2025,
author = {Aminian, Ali and Aljabri, Abdullah and Wang, Sarah and Bena, James and Allende, Daniela S and Rosen, Hana and Arnold, Eileen and Wilson, Rickesha and Milinovich, Alex and Loomba, Rohit and Sanyal, Arun J and Alkhouri, Naim and Wakim-Fleming, Jamile and Laique, Sobia N and Dasarathy, Srinivasan and McCullough, Arthur J and Nissen, Steven E},
title = {Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis},
journal = {Nature Medicine},
year = {2025},
volume = {31},
number = {3},
pages = {988--995},
doi = {10.1038/s41591-024-03480-y}
}
EUVIMED